Business Context and Reporting Period
This Form 6-K, dated November 24, 2014, serves as a circular to shareholders of GlaxoSmithKline plc (GSK) regarding a proposed major, three-part transaction with Novartis AG. The transaction is designed to reshape GSK into a simpler, stronger platform focused on four core franchises: Respiratory, HIV, Vaccines, and Consumer Healthcare. The filing seeks shareholder approval for a "Class 1" transaction, with a General Meeting scheduled for December 18, 2014. The reporting period for the financial data presented covers the years ended December 31, 2011, 2012, and 2013, with GSK's most recent interim results covering the nine months ended September 30, 2014.
Key Financial Metrics
Transaction Consideration
- Oncology Disposal: GSK agreed to sell its Oncology Business to Novartis for an aggregate cash consideration of $16 billion. Up to $1.5 billion is contingent on the results of the COMBI-d clinical trial.
- Vaccines Acquisition: GSK agreed to acquire Novartis's Vaccines Business (excluding influenza) for an initial consideration of $5.255 billion, plus potential milestone payments of up to $1.8 billion and ongoing royalties.
- Consumer Healthcare Joint Venture (JV): GSK and Novartis will form a JV where GSK holds a 63.5% equity interest. The Novartis OTC Business contributed to the JV had 2013 revenues of £1.8 billion.
GSK Group Performance (Nine Months Ended Sept 30, 2014)
- Turnover: £16,820 million (down 3% on a constant exchange rate (CER) basis).
- Core Operating Profit: £4,824 million (down 5% CER).
- Core Earnings Per Share (EPS): 68.0p (down 2% CER).
- Net Debt: £14.8 billion as of September 30, 2014.
- Free Cash Flow: £1,293 million for the nine-month period.
Historical Performance of Acquired/Divested Businesses (2013)
- Novartis OTC Business: Turnover of £1,847 million; Core operating profit of £87 million.
- Novartis Vaccines Business: Turnover of £602 million; Core operating loss of £73 million (due to heavy R&D investment).
- GSK Oncology Business: Turnover of £967 million; Core operating profit of £222 million.
Material Changes and Outlook
The transaction represents a fundamental strategic shift. GSK expects the deal to be accretive to core earnings per share in the first full year following completion. The company anticipates achieving total annual cost savings of approximately £1 billion by the fifth full year post-completion, with 50% delivered by year three. GSK intends to return £4 billion of the net proceeds from the Oncology disposal to shareholders via a B share scheme, subject to shareholder approval and due diligence.
Management commentary highlights that the Oncology Business has shown strong growth (34% in the nine months to September 2014), driven by new launches like Tafinlar and Mekinist. Conversely, the Novartis Vaccines Business returned to growth in 2013, driven by Menveo and Bexsero, though it remains in a heavy investment phase.
Guidance and Risks
- Profit Forecast: GSK expects full-year 2014 core EPS on a CER and ex-divestment basis to be broadly similar to 2013 (base of 108.4p).
- Regulatory Risk: The transaction is conditional on antitrust approvals from the EU Commission, US HSR Act, and other jurisdictions. Divestments (e.g., Nimenrix) may be required to secure clearance.
- Clinical Trial Risk: Up to $1.5 billion of the Oncology sale price is contingent on the COMBI-d trial results. Failure to meet targets could require repayment to Novartis.
- Integration Risk: Challenges in integrating the Novartis OTC and Vaccines businesses, including supply chain disruptions (notably at the Novartis Lincoln, Nebraska facility), could impact operations.
- Legal Contingencies: GSK faces ongoing legal proceedings, including a £301 million fine paid to the Chinese government and investigations by the US DOJ/SEC and UK SFO regarding sales practices.
Investor Verification Checklist
- Verify the outcome of the COMBI-d clinical trial, as it directly impacts the final consideration received for the Oncology Business and the size of the capital return to shareholders.
- Monitor the status of antitrust regulatory approvals and any required divestments (e.g., Nimenrix, smoking cessation assets) that could alter the transaction's scope or value.
- Assess the progress of remediation at the Novartis Lincoln, Nebraska facility, which is critical for the supply chain of the new Consumer Healthcare JV.
- Review the final terms of the £4 billion capital return (B share scheme), including tax implications and the timing of implementation.
- Track the integration of the Novartis Vaccines Business, specifically the vertical integration of antigen supply and the launch of new pipeline products like MenABCWY.
- Confirm the status of ongoing legal investigations (China, US FCPA, UK SFO) and their potential financial impact on the Enlarged Group.